Analysis of genetic and nongenetic factors influencing triglycerides-lowering drug effects based on paired observations

Zheng Xu, Qing Duan, Juan Cui, Yumou Qiu, Qidong Jia, Cong Wu, Jennifer L Clarke

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Obesity is a risk factor for heart disease, stroke, diabetes, high blood pressure, and other chronic diseases. Some drugs, including fenofibrate, are used to treat obesity or excessive weight by lowering the level of specific triglycerides. However, different groups have different drug sensitivities and, consequently, there are differences in drug effects. In this study, we assessed both genetic and nongenetic factors that influence drug responses and stratified patients into groups based on differential drug effect and sensitivity. Our methodology of investigating genetic factors and nongenetic factors is applicable to studying differential effects of other drugs, such as statins, and provides an approach to the development of personalized medicine.

Original languageEnglish (US)
Article number46
JournalBMC Proceedings
Volume12
DOIs
StatePublished - Sep 17 2018

Fingerprint

Triglycerides
Pharmaceutical Preparations
Obesity
Fenofibrate
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Precision Medicine
Blood pressure
Medical problems
Medicine
Heart Diseases
Chronic Disease
Stroke
Hypertension
Weights and Measures

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Analysis of genetic and nongenetic factors influencing triglycerides-lowering drug effects based on paired observations. / Xu, Zheng; Duan, Qing; Cui, Juan; Qiu, Yumou; Jia, Qidong; Wu, Cong; Clarke, Jennifer L.

In: BMC Proceedings, Vol. 12, 46, 17.09.2018.

Research output: Contribution to journalArticle

@article{f97ae020d4a44933b7596cfa310646aa,
title = "Analysis of genetic and nongenetic factors influencing triglycerides-lowering drug effects based on paired observations",
abstract = "Obesity is a risk factor for heart disease, stroke, diabetes, high blood pressure, and other chronic diseases. Some drugs, including fenofibrate, are used to treat obesity or excessive weight by lowering the level of specific triglycerides. However, different groups have different drug sensitivities and, consequently, there are differences in drug effects. In this study, we assessed both genetic and nongenetic factors that influence drug responses and stratified patients into groups based on differential drug effect and sensitivity. Our methodology of investigating genetic factors and nongenetic factors is applicable to studying differential effects of other drugs, such as statins, and provides an approach to the development of personalized medicine.",
author = "Zheng Xu and Qing Duan and Juan Cui and Yumou Qiu and Qidong Jia and Cong Wu and Clarke, {Jennifer L}",
year = "2018",
month = "9",
day = "17",
doi = "10.1186/s12919-018-0153-6",
language = "English (US)",
volume = "12",
journal = "BMC Proceedings",
issn = "1753-6561",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Analysis of genetic and nongenetic factors influencing triglycerides-lowering drug effects based on paired observations

AU - Xu, Zheng

AU - Duan, Qing

AU - Cui, Juan

AU - Qiu, Yumou

AU - Jia, Qidong

AU - Wu, Cong

AU - Clarke, Jennifer L

PY - 2018/9/17

Y1 - 2018/9/17

N2 - Obesity is a risk factor for heart disease, stroke, diabetes, high blood pressure, and other chronic diseases. Some drugs, including fenofibrate, are used to treat obesity or excessive weight by lowering the level of specific triglycerides. However, different groups have different drug sensitivities and, consequently, there are differences in drug effects. In this study, we assessed both genetic and nongenetic factors that influence drug responses and stratified patients into groups based on differential drug effect and sensitivity. Our methodology of investigating genetic factors and nongenetic factors is applicable to studying differential effects of other drugs, such as statins, and provides an approach to the development of personalized medicine.

AB - Obesity is a risk factor for heart disease, stroke, diabetes, high blood pressure, and other chronic diseases. Some drugs, including fenofibrate, are used to treat obesity or excessive weight by lowering the level of specific triglycerides. However, different groups have different drug sensitivities and, consequently, there are differences in drug effects. In this study, we assessed both genetic and nongenetic factors that influence drug responses and stratified patients into groups based on differential drug effect and sensitivity. Our methodology of investigating genetic factors and nongenetic factors is applicable to studying differential effects of other drugs, such as statins, and provides an approach to the development of personalized medicine.

UR - http://www.scopus.com/inward/record.url?scp=85053406902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053406902&partnerID=8YFLogxK

U2 - 10.1186/s12919-018-0153-6

DO - 10.1186/s12919-018-0153-6

M3 - Article

C2 - 30275894

AN - SCOPUS:85053406902

VL - 12

JO - BMC Proceedings

JF - BMC Proceedings

SN - 1753-6561

M1 - 46

ER -